Clinical Trial Update: Efficacy and Safety of Pyrotinib in Patients With HER2 Mutation Advanced Non-Small Cell Lung Cancer [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating the efficacy and safety of pyrotinib in patients with HER2-mutant advanced non-small cell lung cancer.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Drugs mentioned

• Pyrotinib (pyrotinib)

Snippet

Sponsor: Tongji University | Conditions: Non-small Cell Lung Cancer | Phase 2 | Status: UNKNOWN